Compare Dell Technologies Inc (DELL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Dell Technologies Inc trades at $586.28 (market cap $365.31B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Dell Technologies Inc is far larger — about 170.7× Recursion Pharmaceuticals Inc's market cap, and Dell Technologies Inc pays a 0.44% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DELL | RXRX | |
|---|---|---|
Market Cap | $365.31B | $2.14B |
Volume | 5,121,365 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $588.67 | $6.79 |
52-Week Low | $111.10 | $2.84 |
Typical Hold Time | 57 Days | 23 Days |
Enterprise Value | $388.20B | $1.66B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies trades at $574.74, down 0.73% on the day, with strong bullish momentum driven by AI server demand. The stock shows robust earnings performance with three consecutive quarterly beats and raised 2027 AI revenue guidance to $74 billion. Technical indicators signal bullish momentum while fundamentals reveal strong revenue growth and improving profit margins, though valuation multiples appear elevated.
Outlook remains positive with AI server backlog reaching $95 billion and institutional support, though risks include execution challenges and competitive pressures in the rapidly evolving AI infrastructure market. The stock trades near analyst consensus target of $566.35 with upside potential to $735 based on AI-driven growth prospects.
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
